Rebeka Bustamante Rocha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebeka Bustamante Rocha has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Luiz Boechat
Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas , Manaus, Amazonas
2 shared publications - Emanuelly Maria Lima Barbosa
Programa de Educação Tutorial PET Medicina, Faculdade de Medicina, Universidade Federal do Amazonas
2 shared publications - Fernanda Ferreira Bomtempo
School of Medicine, Medical Sciences Faculty of Minas Gerais, Belo Horizonte, Brazil
2 shared publications - Gabriela Borges Nager
Faculty of Medicine, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
2 shared publications - Giulia Isadora Cenci
School of Medicine, Faculdade Meridional, Passo Fundo, Brazil
2 shared publications - Isabela De Araujo Seffair
Programa de Educação Tutorial PET Medicina, Faculdade de Medicina, Universidade Federal do Amazonas
2 shared publications
Latest Publications
- 20 May 2026
- Published by Wiley in Health Services Research
- Vol. 61 (3) , e70133
Gabapentinoid Polypharmacy Among Medicare Beneficiaries During the Poststroke Recovery Period
Objective: To describe patterns of gabapentinoid (Gabapentin and Pregabalin) use and concurrent use with other central nervous system (CNS) acting pain medications (opioids and benzodiazepines) among US Medicare beneficiaries following acute ischemic stroke (AIS). Study Setting and Design: We analyzed new outpatient gabapentinoid prescriptions in older stroke survivors between 2009 and 2022. We calculated the percent of new gabapentinoid initiators within 6 months of stroke discharge and analyzed concurrent pain medications prescribed within 30 days of gabapentinoid initiation. We presented trends and geographic patterns standardized by age, discharge destination, and modified Rankin Scale (mRS) to control for variations in the sample composition by age and stroke severity over time. Data Sources and Analytic Sample: We analyzed a 20% sample of US Medicare beneficiaries aged 65 years or older who were hospitalized for AIS. We included those who met Medicare enrollment criteria, had no prior stroke, no prior gabapentinoid use within 6 months, and were discharged home within 30 days of hospitalization. Principal Findings: Among 153,728 stroke survivors, 4.9% received new gabapentinoid prescriptions within 6 months postdischarge. Of the 7595 gabapentinoid initiators, 1579 (21%) had concurrent opioid and 653 (8.6%) had concurrent benzodiazepine prescriptions. In the sample, the median age was 78 years (Quartile Range: 72–84), 55% were female, and 81% were non‐Hispanic White. The standardized percentage of gabapentinoid initiators increased from 3.8% in 2009 to 5.9% in 2022 (crude: 3.6% in 2009 to 5.8% in 2022). Despite increases in the number of gabapentinoid initiators, the percentage of concurrent opioid users remained low over time, around 1% of the study population. We observed variation in gabapentinoid initiation and concurrent use with opioids by geography. Conclusions: From 2009 to 2022, poststroke gabapentinoid use increased in older adults, but concurrent use with opioids remained low over time.
- 20 May 2026
- Published by Wiley in Health Services Research
- Vol. 61 (3) , e70133
Gabapentinoid Polypharmacy Among Medicare Beneficiaries During the Poststroke Recovery Period
Objective: To describe patterns of gabapentinoid (Gabapentin and Pregabalin) use and concurrent use with other central nervous system (CNS) acting pain medications (opioids and benzodiazepines) among US Medicare beneficiaries following acute ischemic stroke (AIS). Study Setting and Design: We analyzed new outpatient gabapentinoid prescriptions in older stroke survivors between 2009 and 2022. We calculated the percent of new gabapentinoid initiators within 6 months of stroke discharge and analyzed concurrent pain medications prescribed within 30 days of gabapentinoid initiation. We presented trends and geographic patterns standardized by age, discharge destination, and modified Rankin Scale (mRS) to control for variations in the sample composition by age and stroke severity over time. Data Sources and Analytic Sample: We analyzed a 20% sample of US Medicare beneficiaries aged 65 years or older who were hospitalized for AIS. We included those who met Medicare enrollment criteria, had no prior stroke, no prior gabapentinoid use within 6 months, and were discharged home within 30 days of hospitalization. Principal Findings: Among 153,728 stroke survivors, 4.9% received new gabapentinoid prescriptions within 6 months postdischarge. Of the 7595 gabapentinoid initiators, 1579 (21%) had concurrent opioid and 653 (8.6%) had concurrent benzodiazepine prescriptions. In the sample, the median age was 78 years (Quartile Range: 72–84), 55% were female, and 81% were non‐Hispanic White. The standardized percentage of gabapentinoid initiators increased from 3.8% in 2009 to 5.9% in 2022 (crude: 3.6% in 2009 to 5.8% in 2022). Despite increases in the number of gabapentinoid initiators, the percentage of concurrent opioid users remained low over time, around 1% of the study population. We observed variation in gabapentinoid initiation and concurrent use with opioids by geography. Conclusions: From 2009 to 2022, poststroke gabapentinoid use increased in older adults, but concurrent use with opioids remained low over time.
- 4 September 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 91, 105868
Heterogenous relapse and efficacy endpoint definitions for neuromyelitis optica spectrum disorder studies: A systematic review
- 4 September 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 91, 105868
Heterogenous relapse and efficacy endpoint definitions for neuromyelitis optica spectrum disorder studies: A systematic review
- 4 December 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (5) , 2119-2125
Efficacy of transcranial direct current stimulation in patients with dysphagia after stroke: a systematic review
Background Swallowing is a complex function that can be disrupted after stroke. Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation therapy that recently has been tested to treat stroke-related dysphagia. Methods The authors performed a search in the literature to review the described evidence of the use of tDCS in dysphagia after stroke. Three electronic databases were searched. The risk of bias evaluation was carried out through the RoB-2 tool. The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework was also implemented. Results Of 265 articles, only nine studies were included in this review. The most common location of the tDCS stimulation was the unaffected hemisphere (44%). Regarding the outcome measure, the Dysphagia Outcome and Severity Scale (DOSS) was the most commonly used (55%). However, due to the high heterogeneity of the protocols, and considering the differences between the types of stroke, the authors opted not to perform a metanalysis. Instead, a systematic review with a thorough analysis of each individual study and the impact of the differences to the outcomes was preferred. Conclusions The final considerations are that even though the majority of studies described benefits from tDCS in post-stroke dysphagia, as they present too many methodological differences, it is not possible to compare them. In addition, many articles included patients with less than 6 months after stroke, which is an important bias as the swallowing function can be recovered spontaneously within this period, turning the certainty of the evidence really low.
- 4 December 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (5) , 2119-2125
Efficacy of transcranial direct current stimulation in patients with dysphagia after stroke: a systematic review
Background Swallowing is a complex function that can be disrupted after stroke. Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation therapy that recently has been tested to treat stroke-related dysphagia. Methods The authors performed a search in the literature to review the described evidence of the use of tDCS in dysphagia after stroke. Three electronic databases were searched. The risk of bias evaluation was carried out through the RoB-2 tool. The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework was also implemented. Results Of 265 articles, only nine studies were included in this review. The most common location of the tDCS stimulation was the unaffected hemisphere (44%). Regarding the outcome measure, the Dysphagia Outcome and Severity Scale (DOSS) was the most commonly used (55%). However, due to the high heterogeneity of the protocols, and considering the differences between the types of stroke, the authors opted not to perform a metanalysis. Instead, a systematic review with a thorough analysis of each individual study and the impact of the differences to the outcomes was preferred. Conclusions The final considerations are that even though the majority of studies described benefits from tDCS in post-stroke dysphagia, as they present too many methodological differences, it is not possible to compare them. In addition, many articles included patients with less than 6 months after stroke, which is an important bias as the swallowing function can be recovered spontaneously within this period, turning the certainty of the evidence really low.
- Open Access
- 31 May 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (05) , 475-483
Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
Background Several randomized clinical trials (RCTs) have shown that dual orexin receptor antagonists (DORAs) are effective in the treatment of chronic insomnia. However, the superiority of one particular DORA over the others remains unclear. Objective To perform a network meta-analysis to evaluate the efficacy of different DORAs in patients with chronic insomnia. Methods The Medline, Embase, and Cochrane Central databases were searched for RCTs that compared DORA with placebo in patients ≥ 18 years of age with a diagnosis of insomnia disorder. We pooled outcomes for wake time after sleep onset (WASO), latency to persistent sleep (LPS), total sleep time (TST), and adverse events (AEs). Results We included 10 RCTs with 7,806 patients, 4,849 of whom received DORAs as the intervention. Overall, we found that DORAs were associated with the improvement of all analyzed efficacy outcomes. Concerning TST, an apparent dose-dependent pattern was noticed, with higher doses relating to a longer TST. Lemborexant 10mg provided the largest reduction in WASO (at month 1) in minutes (standardized mean difference [SMD] = -25.40; 95% confidence interval [95%CI] = -40.02–-10.78), followed by suvorexant 20/15mg (SMD = -25.29; 95%CI = -36.42–-14.15), which also appeared to provide the largest decrease in long-term WASO (SMD = -23.70; 95%CI = -35.89–-11.51). The most frequent AEs were somnolence, nasopharyngitis, and headache, with rates of up to 14.8%. Conclusion Our results suggest that DORAs are associated with greater efficacy when compared with placebo in the treatment of insomnia, a complex 24-hour sleep disorder. Additionally, dosing might play an important role in the management of chronic insomnia.
- 31 May 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (05) , 475-483
Open AccessDual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
Background Several randomized clinical trials (RCTs) have shown that dual orexin receptor antagonists (DORAs) are effective in the treatment of chronic insomnia. However, the superiority of one particular DORA over the others remains unclear. Objective To perform a network meta-analysis to evaluate the efficacy of different DORAs in patients with chronic insomnia. Methods The Medline, Embase, and Cochrane Central databases were searched for RCTs that compared DORA with placebo in patients ≥ 18 years of age with a diagnosis of insomnia disorder. We pooled outcomes for wake time after sleep onset (WASO), latency to persistent sleep (LPS), total sleep time (TST), and adverse events (AEs). Results We included 10 RCTs with 7,806 patients, 4,849 of whom received DORAs as the intervention. Overall, we found that DORAs were associated with the improvement of all analyzed efficacy outcomes. Concerning TST, an apparent dose-dependent pattern was noticed, with higher doses relating to a longer TST. Lemborexant 10mg provided the largest reduction in WASO (at month 1) in minutes (standardized mean difference [SMD] = -25.40; 95% confidence interval [95%CI] = -40.02–-10.78), followed by suvorexant 20/15mg (SMD = -25.29; 95%CI = -36.42–-14.15), which also appeared to provide the largest decrease in long-term WASO (SMD = -23.70; 95%CI = -35.89–-11.51). The most frequent AEs were somnolence, nasopharyngitis, and headache, with rates of up to 14.8%. Conclusion Our results suggest that DORAs are associated with greater efficacy when compared with placebo in the treatment of insomnia, a complex 24-hour sleep disorder. Additionally, dosing might play an important role in the management of chronic insomnia.
- Open Access
- 2 August 2020
- Published by MDPI AG in Preprints.org
SARS-CoV-2 and Covid-19 Immunopathogenesis
The coronavirus disease 2019 (COVID-19) is now a global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike other known coronaviruses, such as the Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 reveals new clinical, immunological, and pathologic features. The lymphocyte depletion, macrophage and neutrophil hyperactivation, cytokine dysregulation, thrombophilia, delayed antiviral response, and immune exhaustion are key immunological findings linked to the clinical progression of this disease. Understanding and identifying the underlying immunological basis of COVID-19 is crucial to designing effective therapies. Here, we provide an overview of immunopathogenesis driven by SARS-CoV-2 after its interactions with the immune system.
- 2 August 2020
- Published by MDPI AG in Preprints.org
Open AccessSARS-CoV-2 and Covid-19 Immunopathogenesis
The coronavirus disease 2019 (COVID-19) is now a global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike other known coronaviruses, such as the Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 reveals new clinical, immunological, and pathologic features. The lymphocyte depletion, macrophage and neutrophil hyperactivation, cytokine dysregulation, thrombophilia, delayed antiviral response, and immune exhaustion are key immunological findings linked to the clinical progression of this disease. Understanding and identifying the underlying immunological basis of COVID-19 is crucial to designing effective therapies. Here, we provide an overview of immunopathogenesis driven by SARS-CoV-2 after its interactions with the immune system.
- Open Access
- 22 April 2020
- Published by Universidade Federal do Tocantins in DESAFIOS - Revista Interdisciplinar da Universidade Federal do Tocantins
- Vol. 7 (Especial-3) , 97-108
IMUNOTERAPIAS NO TRATAMENTO DA COVID-19
A COVID-19 é uma doença causada pelo novo coronavírus e se tornou-se ameaça mundial pouco tempo após seu surgimento na cidade chinesa de Wuhan. Desde Dezembro de 2019, diversas pesquisas estão sendo realizadas com o propósito de conter a disseminação do vírus e de se obter medidas de tratamento úteis no combate à pandemia. Com isso, o presente estudo volta-se para a análise das novas metodologias de caráter terapêutico que estão sendo desenvolvidas mundialmente para o tratamento e prevenção da COVID-19. A presente revisão bibliográfica foi realizada com os dados obtidos nas seguintes bases: SciELO, Medline, Scopus, Up-to-Date, dentre outros recursos atuais e relevantes para a temática, que foram publicados no primeiro trimestre do ano de 2020. Com esta abordagem foram identificadas diversas abordagens de tratamento ainda em desenvolvimento, com diferentes modelos, bem como mecanismo de ação de novas medidas terapêuticas e de imunização, sobretudo, as que utilizam soro, imunoglobulinas, anticorpos monoclonais, plasma de pacientes convalescentes e vacinas. O sistema de saúde mundial urge pela criação de uma vacina capaz de estabelecer a memória imunológica na população. Novos estudos mostram-se promissores em relação a essa criação, todavia, as medidas profiláticas permanecem como prioridade máxima e indispensáveis.
- 22 April 2020
- Published by Universidade Federal do Tocantins in DESAFIOS - Revista Interdisciplinar da Universidade Federal do Tocantins
- Vol. 7 (Especial-3) , 97-108
Open AccessIMUNOTERAPIAS NO TRATAMENTO DA COVID-19
A COVID-19 é uma doença causada pelo novo coronavírus e se tornou-se ameaça mundial pouco tempo após seu surgimento na cidade chinesa de Wuhan. Desde Dezembro de 2019, diversas pesquisas estão sendo realizadas com o propósito de conter a disseminação do vírus e de se obter medidas de tratamento úteis no combate à pandemia. Com isso, o presente estudo volta-se para a análise das novas metodologias de caráter terapêutico que estão sendo desenvolvidas mundialmente para o tratamento e prevenção da COVID-19. A presente revisão bibliográfica foi realizada com os dados obtidos nas seguintes bases: SciELO, Medline, Scopus, Up-to-Date, dentre outros recursos atuais e relevantes para a temática, que foram publicados no primeiro trimestre do ano de 2020. Com esta abordagem foram identificadas diversas abordagens de tratamento ainda em desenvolvimento, com diferentes modelos, bem como mecanismo de ação de novas medidas terapêuticas e de imunização, sobretudo, as que utilizam soro, imunoglobulinas, anticorpos monoclonais, plasma de pacientes convalescentes e vacinas. O sistema de saúde mundial urge pela criação de uma vacina capaz de estabelecer a memória imunológica na população. Novos estudos mostram-se promissores em relação a essa criação, todavia, as medidas profiláticas permanecem como prioridade máxima e indispensáveis.